Curated News
By: NewsRamp Editorial Staff
August 10, 2026

Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma's FDA-approved MS drug trial offers early investors a potential edge in a multi-billion-dollar market.
  • Quantum BioPharma's Lucid-MS targets PAD2 to inhibit demyelination, with Phase 2 trial evaluating safety and efficacy in MS patients.
  • Quantum BioPharma's Lucid-MS aims to reverse myelin damage, offering hope for improved mobility and quality of life for MS patients.
  • Lucid-MS is a first-in-class drug that could prevent and reverse myelin breakdown, differentiating it from existing MS treatments.

Impact - Why it Matters

This FDA approval marks a significant milestone for Quantum BioPharma and the MS community. If Lucid-MS proves effective in Phase 2, it could offer a new treatment option that not only manages symptoms but potentially halts or reverses the progression of multiple sclerosis, a chronic and often debilitating disease. For investors, this development could enhance the company's valuation and future prospects, as Lucid-MS addresses an unmet medical need. For patients, it brings hope for a therapy that targets the underlying cause of MS rather than just the immune response.

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received FDA approval for its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), a first-in-class multiple sclerosis (MS) candidate. This clearance allows the company to proceed into Phase 2 clinical development, with a randomized, double-blind, placebo-controlled study planned to evaluate efficacy, safety, and tolerability in people with MS. The trial will use clinical and radiological measures to assess outcomes. Start-up activities, including site selection, are underway, and patient enrollment is expected to begin as soon as possible. The company's full press release provides further details.

Unlike existing MS therapies that primarily modulate the immune system, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination. It targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation, and has shown the ability to prevent and reverse myelin breakdown in preclinical models. Prior Phase 1 trials in healthy participants demonstrated a favorable safety profile and good tolerability. As of March 31, 2026, Quantum BioPharma reported over $10 million in cash, digital assets, and liquid investments to support the upcoming trials.

Quantum BioPharma is dedicated to developing innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders. Its lead compound, Lucid-MS, is a patented new chemical entity. The company also holds a 19.84% stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% of sales from unbuzzd(TM) until $250 million is reached, after which the royalty drops to 3% in perpetuity. For more updates on QNTM, visit the company's newsroom. This news was disseminated by InvestorWire, a specialized communications platform.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial

blockchain registration record for this content.